W1915 Omega-3 and Omega-6 Fatty Acids in Colorectal Cancer Patients in Relation to Tumor Localization

SummaryBackground: Polyunsaturated fatty acids (PUFAs) play a role in the development/progression of colon cancer. The aim of the study was to assess the relation between serum phospholipids PUFAs, colorectal tumour localization and disease progression. Methods: A total of 67 patients (18 with proximal colon, 17 with distal colon and 32 with rectal tumour localization) as well as 16 controls were studied. One year after surgery, 33 patients had disease progression. Serum levels of C16:1(n-7), C18:1(n-9), C18:3(n-3), C20:5(n-3), C22:6(n- 3), C18:2(n-6), C20:2(n-6), C20:4(n-6) fatty acids of se - rum phospholipids were quantitatively measured before surgery by gas-chromatography. Results: Significantly higher mean value of C18:2, as compared to control, has been noted only for patients with proximal (p<0.05) and distal tumour (p<0.03) localization. The lower mean level of C20:5 and unsaturation index (UI) were observed in colorectal cancer patients regardless the tumour localization, but the statistical difference was noted only for patients with proximal tumours (p<0.05, p<0.03). In patients with proximal tumours, significantly lower mean level of C20:4 and UI were noted in patients with disease progression, as compared to patients with proximal tumours without disease progression (p<0.05). Conclusion: The evaluation of PUFAs as a risk/prognostic factor in colorectal cancer patients should take into account tumour localization as a dependent variable.

Download Full-text

KCNB1 gene polymorphisms and related indel as predictor biomarkers of treatment response for colorectal cancer – toward a personalized medicine

Tumor Biology ◽

10.1177/1010428320925237 ◽

2020 ◽

Vol 42 (6) ◽

pp. 101042832092523 ◽

Cited By ~ 2

Author(s):

Mouadh Barbirou ◽

Ikram Sghaier ◽

Sinda Bedoui ◽

Rahma Ben Abderrazek ◽

Hazar Kraiem ◽

...

Keyword(s):

Colorectal Cancer ◽

Treatment Response ◽

Cancer Patients ◽

Serum Levels ◽

Amplification Refractory Mutation System ◽

Specific Response ◽

Tumor Localization ◽

Gene Variants ◽

Treatment And Prevention ◽

Colorectal Cancer Patients

The KCNB1 gene variants were differentially associated with cancers. However, their association with colorectal cancer has not yet been explored. We investigated the contribution of the KCNB1 gene variants rs3331, rs1051295, and indel (insertion/deletion) rs11468831 Polymorphism as predictors of the treatment response in colorectal cancer patients. A retrospective study, which involved 291 Tunisian colorectal cancer patients (aged 60.0 ± 13.1 years), who were stratified into responder and non-responder groups, according to TNM stages and their responsiveness to chemotherapy based on fluorouracil. KCNB1 genotyping was performed with amplification-refractory mutation system–polymerase chain reaction, and was confirmed by Sanger sequencing. Sex-specific response was found and colorectal cancer females are less likely to achieve a positive response during the chemotherapy strategy, compared to males. Weight and body mass index, tumor size, and tumor localization are considered as predictive factors to treatment responsiveness. Carriage of rs11468831 Ins allele was significantly associated with successful therapy achievement ( p adjusted < 0.001). Stratification of colorectal cancer patients’ response according to tumor localization and TNM stages reveals negative association of rs3331 Major allele to treatment response among the patients with advanced cancer stages (subgroup G2). The presence of rs3331 (homozygous minor) C/C genotype was positively associated with decline in carcino-embryonic antigen ( p = 0.043) and CA19-9 ( p = 0.014) serum levels. On the other hand, the presence of rs1051295 (homozygous minor) A/A genotype was correlated with marked decline in CA19-9 serum levels. KCNB1 haplotype did not reveal any association between haplotypes and treatment response. The results obtained suggest that gender-specific strategies for screening treatment and prevention protocols as well as KCNB1 variants may constitute an effective model for ongoing personalization medicine.

Download Full-text

STUDY OF THE LEVEL OF FATTY ACIDS IN ERYTHROCYTE MEMBRANES AND SERUM OF PATIENTS WITH COLORECTAL CANCER IN NOVOSIBIRSK

Advances in molecular oncology ◽

10.17650/2313-805x-2018-5-2-50-61 ◽

2018 ◽

Vol 5 (2) ◽

pp. 50-61 ◽

Cited By ~ 2

Author(s):

M. V. Kruchinina ◽

V. N. Kruchinin ◽

Ya. I. Prudnikova ◽

A. A. Gromov ◽

M. V. Shashkov ◽

...

Keyword(s):

Colorectal Cancer ◽

Fatty Acids ◽

Monounsaturated Fatty Acids ◽

Erythrocyte Membranes ◽

Control Group ◽

Study Group ◽

Omega 3 ◽

Healthy Individuals ◽

Internal Organs ◽

Omega 6

The objectiveis to measure the level of fatty acids in erythrocyte membranes and serum of patients with colorectal cancer.Materials and methods.The study group included 100 patients with diagnosed colorectal cancer (57 men and 43 women). The control group included 24 reasonably healthy people (14 men and 10 women) matched for age and sex, without malignant cancers or manifested pathology of the internal organs.Results.Decreased levels of saturated, monounsaturated fatty acids and increased levels of polyunsaturated fatty acids (PUFAs) in erythrocyte membranes and serum (p <0.0001–0.05) were observed. The levels of omega-3 PUFAs in colorectal cancer exceeded the levels in healthy individuals both in erythrocyte membranes and in serum; for omega-6 PUFAs only a trend was observed. At the same time, the ratio of omega-6/omega-3 PUFAs in colorectal cancer was lower than in control (p <0.0001–0.002). The state of erythrocyte membranes more significantly and for more parameters characterized differences between the groups than serum. The most discriminating parameters between patients with colorectal cancer and healthy individuals both in erythrocyte membranes and serum were the levels of C20:2;11,14 (eicosadienoic), C20:3;8,11,14 (dihomo-γ-linolenic), C20:4;5,8,11,14 (eicosatetraenoic, arachidonic), C22:5;7,10,13,16,19 (docosapentaenoic), and C22:6;4,7,10,13,16,19 (docosahexaenoic) PUFAs.

Download Full-text

Effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with colorectal cancer: a study protocol for a double blind randomized controlled trial

Trials ◽

10.1186/s13063-019-3719-3 ◽

2019 ◽

Vol 20 (1) ◽

Cited By ~ 2

Author(s):

Fatemeh Haidari ◽

Behnaz Abiri ◽

Masood Iravani ◽

Seyed-Mohsen Razavi ◽

Parvin Sarbakhsh ◽

...

Keyword(s):

Colorectal Cancer ◽

Fatty Acids ◽

Vitamin D ◽

Nutritional Status ◽

Tumor Marker ◽

Inflammatory Biomarkers ◽

Omega 3 Fatty Acids ◽

Omega 3 ◽

Double Blind ◽

Colorectal Cancer Patients

Abstract Background Much evidence is available demonstrating that both vitamin D and omega-3 fatty acids block the development and progression of colonic carcinogenesis. The results of animal studies have shown that the consumption of omega-3 fatty acids can decrease inflammatory biomarkers, enhance the efficacy of chemotherapy, and decrease the side effects of chemotherapy or cancer. Also, observational studies propose that higher levels of 25(OH)D are related to improved survival of colorectal cancer patients. This study will aim to evaluate the effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in colorectal cancer patients. Methods/design We will carry out an 8-week double-blind randomized, placebo-controlled clinical trial to evaluate the effects of vitamin D and omega-3 fatty acids co-supplementation on inflammatory biomarkers, tumor marker CEA, and nutritional status in patients with stage ӀӀ or ӀӀӀ colorectal cancer undergoing chemotherapy. Discussion Because of the important effects of vitamin D and omega-3 fatty acids on molecular pathways involved in cancer development and progression, it seems that both vitamin D and omega-3 fatty acids may provide a new adjuvant therapy by decreasing inflammatory biomarkers and resistance to cancer treatment in patients with colorectal cancer. Trial registration Iranian Registry of Clinical Trials IRCT20180306038979N1. Registered on 16 March 2018.

Download Full-text

Fecal metabolome and microflora differences between colorectal cancer patients and healthy adults.

Journal of Clinical Oncology ◽

10.1200/jco.2013.31.15_suppl.11050 ◽

2013 ◽

Vol 31 (15_suppl) ◽

pp. 11050-11050 ◽

Cited By ~ 1

Author(s):

Tiffany Weir ◽

Robert Frederick Marschke ◽

Regina J. Brown ◽

Joanne O'Malia ◽

Erica Dickson ◽

...

Keyword(s):

Colorectal Cancer ◽

Fatty Acids ◽

Cancer Patients ◽

454 Pyrosequencing ◽

Monounsaturated Fatty Acids ◽

Short Chain Fatty Acids ◽

Healthy Adults ◽

Gas Chromatography Mass Spectrometry ◽

Stool Samples ◽

Colorectal Cancer Patients

11050 Background: High throughput genomic technologies such as 454 pyrosequencing and metabolomics platforms are now available to explore the relationships between gastrointestinal microflora, metabolism and colorectal cancer (CRC). Recent efforts to characterize the colorectal cancer microbiome have led to the identification of numerous bacteria whose presence or absence is associated with diseased tissue. Methods: Stool samples were collected from 10 healthy adults and 11 colorectal cancer patients prior to surgery at the University of Colorado Health-Poudre Valley Hospital in Fort Collins, CO. Fecal samples were processed for isolation of microbial DNA and sequenced using the 454 pyrosequencing platform. Metabolites were extracted using acidified water for short chain fatty acids (SCFA) and 3:2:2 isopropanol:acetonitrile:water to obtain global metabolite profiles utilizing Gas Chromatography-Mass Spectrometry (GC-MS). Results: There were no significant differences in the overall microbial community structure associated with disease state, but several bacterial genera, particularly butyrate-producing species, were under-represented in the CRC samples, while a mucin-degrading species, Akkermansia muciniphila, was about 4-fold higher in CRC (p<0.01). Consequently, the chemoprotective SCFA, butyrate, was significantly lower in CRC samples than in those from healthy adults (p<0.0001) and GC-MS profiling revealed that there were higher levels of amino acids in stool samples from CRC patients and higher poly and monounsaturated fatty acids in stool from healthy adults (p<0.01). Conclusions: This systems biology approach may allow us to identify functional groups of gastrointestinal bacteria and their associated metabolites as novel therapeutic and chemopreventive targets. The Colorado Agricultural Experiment Station, Shipley Foundation and the NIH R03CA150070 supported this work.

Download Full-text

Metabolomics Analysis for Defining Serum Biochemical Markers in Colorectal Cancer Patients with Qi Deficiency Syndrome or Yin Deficiency Syndrome

Evidence-based Complementary and Alternative Medicine ◽

10.1155/2017/7382752 ◽

2017 ◽

Vol 2017 ◽

pp. 1-10 ◽

Cited By ~ 8

Author(s):

Fangfang Tao ◽

Ping Lü ◽

Chunbo Xu ◽

Mengmeng Zheng ◽

Wenhong Liu ◽

...

Keyword(s):

Colorectal Cancer ◽

Amino Acids ◽

Fatty Acids ◽

Cancer Patients ◽

Biochemical Markers ◽

Deficiency Syndrome ◽

Metabolic Profiles ◽

Yin Deficiency ◽

Colorectal Cancer Patients ◽

Metabolomics Analysis

Colorectal cancer is one of the leading causes of tumor-associated death, and traditional Chinese medicine (TCM) classifies colorectal cancer into various subtypes mainly according to the symptomatic pattern identification (ZHENG). Here, we investigated the difference in metabolic profiles of serum by comparing colorectal cancer subjects with Nondeficiency (ND), Qi deficiency (QD), and Yin deficiency (YD). The ratio of subjects with carcinoembryonic antigen (CEA) was higher in YD pattern, and the ratio of subjects with carbohydrate antigen 19-9 (CA19-9) was higher both in YD and in QD, compared with ND. As a result of metabolomics analysis, twenty-five metabolites displayed differences between QD and ND, while twenty-eight metabolites displayed differences between YD and ND. The downregulated metabolites in QD/ND and YD/ND mainly include carbohydrates and the upregulated metabolites mainly include amino acids and fatty acids, suggesting conversion obstruction of carbohydrates, fatty acids, and amino acids occurs in patients with QD and YD compared with ND. Our results demonstrate that colorectal cancer patients with QD or YD were associated with metabolic disorders and the variations of serum metabolic profiles may serve as potential biochemical markers for diagnosis and prognosis of colorectal cancer patients displayed QD or YD patterns.

Download Full-text